{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:12:55Z","timestamp":1788401575121,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Ethics"],"DOI":"10.1186\/s12910-026-01534-z","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:16:58Z","timestamp":1782170218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Motivations and experiences in controlled human infection trials vs. phase I clinical trials: a survey study"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5529-2839","authenticated-orcid":false,"given":"Victor M","family":"Cnossen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia A. C","family":"Lamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier P","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Zimmer-Harwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meta","family":"Roestenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M. C","family":"Kamerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Astrid","family":"Hoogerwerf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"4","key":"1534_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/120347549800200413","volume":"2","author":"JJ Muglia","year":"1998","unstructured":"Muglia JJ, DiGiovanna JJ. Phase 1 Clinical Trials. J Cutan Med Surg. 1998;2(4):236\u201341. https:\/\/doi.org\/10.1177\/120347549800200413.","journal-title":"J Cutan Med Surg"},{"key":"1534_CR2","unstructured":"World Health Organization. WHO guidance on the ethical conduct of controlled human infection studies. 1st ed. Geneva: World Health Organization; 2021. ISBN 978-92-4-003781-6."},{"key":"1534_CR3","doi-asserted-by":"publisher","first-page":"251513552413083","DOI":"10.1177\/25151355241308305","volume":"12","author":"VM Cnossen","year":"2024","unstructured":"Cnossen VM, van Leeuwen RP, Mazur NI, et al. From setbacks to success: lessons from the journey of RSV vaccine development. Therapeutic Adv Vaccines Immunotherapy. 2024;12:25151355241308305. https:\/\/doi.org\/10.1177\/25151355241308305.","journal-title":"Therapeutic Adv Vaccines Immunotherapy"},{"issue":"12","key":"1534_CR4","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1016\/S1473-3099(23)00294-3","volume":"23","author":"YN Abo","year":"2023","unstructured":"Abo YN, Jamrozik E, McCarthy JS, Roestenberg M, Steer AC, Osowicki J. Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy. Lancet Infect Dis. 2023;23(12):e533\u201346. https:\/\/doi.org\/10.1016\/S1473-3099(23)00294-3.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"1534_CR5","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S1473-3099(18)30177-4","volume":"18","author":"M Roestenberg","year":"2018","unstructured":"Roestenberg M, Hoogerwerf MA, Ferreira DM, Mordm\u00fcller B, Yazdanbakhsh M. Experimental infection of human volunteers. Lancet Infect Dis. 2018;18(10):e312\u201322. https:\/\/doi.org\/10.1016\/S1473-3099(18)30177-4.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"1534_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s13063-019-3843-0","volume":"20","author":"R Palacios","year":"2019","unstructured":"Palacios R, Shah SK. When could human challenge trials be deployed to combat emerging infectious diseases? Lessons from the case of a Zika virus human challenge trial. Trials. 2019;20(Suppl 2):702. https:\/\/doi.org\/10.1186\/s13063-019-3843-0.","journal-title":"Trials"},{"issue":"8","key":"1534_CR7","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1016\/S1473-3099(20)30438-2","volume":"20","author":"E Jamrozik","year":"2020","unstructured":"Jamrozik E, Selgelid MJ. COVID-19 human challenge studies: ethical issues. Lancet Infect Dis. 2020;20(8):e198\u2013203. https:\/\/doi.org\/10.1016\/S1473-3099(20)30438-2.","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"1534_CR8","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1056\/NEJMp0801872","volume":"358","author":"C Elliott","year":"2008","unstructured":"Elliott C, Abadie R. Exploiting a Research Underclass in Phase 1 Clinical Trials. N Engl J Med. 2008;358(22):2316\u20137. https:\/\/doi.org\/10.1056\/NEJMp0801872.","journal-title":"N Engl J Med"},{"issue":"4","key":"1534_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bioe.12736","volume":"34","author":"A Binik","year":"2020","unstructured":"Binik A. What risks should be permissible in controlled human infection model studies? Bioethics. 2020;34(4):420\u201330. https:\/\/doi.org\/10.1111\/bioe.12736.","journal-title":"Bioethics"},{"issue":"6385","key":"1534_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1126\/science.aaq0917","volume":"360","author":"SK Shah","year":"2018","unstructured":"Shah SK, Kimmelman J, Lyerly AD, et al. Bystander risk, social value, and ethics of human research. Science. 2018;360(6385):158\u20139. https:\/\/doi.org\/10.1126\/science.aaq0917.","journal-title":"Science"},{"key":"1534_CR11","doi-asserted-by":"publisher","first-page":"101747","DOI":"10.1016\/j.biologicals.2024.101747","volume":"85","author":"M Kapulu","year":"2024","unstructured":"Kapulu M, Manda-Taylor L, Balasingam S, et al. Fourth Controlled Human Infection Model (CHIM) meeting \u2013 CHIMs in endemic countries, May 22\u201323, 2023. Biologicals. 2024;85:101747. https:\/\/doi.org\/10.1016\/j.biologicals.2024.101747.","journal-title":"Biologicals"},{"issue":"1","key":"1534_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/phe\/phv026","volume":"9","author":"B Bambery","year":"2016","unstructured":"Bambery B, Selgelid M, Weijer C, Savulescu J, Pollard AJ. Ethical Criteria for Human Challenge Studies in Infectious Diseases. Public Health Ethics. 2016;9(1):92\u2013103. https:\/\/doi.org\/10.1093\/phe\/phv026.","journal-title":"Public Health Ethics"},{"issue":"7","key":"1534_CR13","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1086\/322664","volume":"33","author":"GM Franklin","year":"2001","unstructured":"Franklin GM, Grady C. The Ethical Challenge of Infection-Inducing Challenge Experiments. Clin Infect Dis. 2001;33(7):1028\u201333. https:\/\/doi.org\/10.1086\/322664.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1534_CR14","doi-asserted-by":"publisher","first-page":"e033796","DOI":"10.1136\/bmjopen-2019-033796","volume":"10","author":"MA Hoogerwerf","year":"2020","unstructured":"Hoogerwerf MA, de Vries M, Roestenberg M. Money-oriented risk-takers or deliberate decision-makers: a cross-sectional survey study of participants in controlled human infection trials. BMJ Open. 2020;10(7):e033796. https:\/\/doi.org\/10.1136\/bmjopen-2019-033796.","journal-title":"BMJ Open"},{"issue":"8","key":"1534_CR15","doi-asserted-by":"publisher","first-page":"e0328378","DOI":"10.1371\/journal.pone.0328378","volume":"20","author":"AG Mack","year":"2025","unstructured":"Mack AG, Halperin DM, Selig BM, Condran BR, Halperin SA. Exploring the participant experience in controlled human infection model (CHIM) trials: A modified grounded theory study. PLoS ONE. 2025;20(8):e0328378. https:\/\/doi.org\/10.1371\/journal.pone.0328378.","journal-title":"PLoS ONE"},{"key":"1534_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.12688\/wellcomeopenres.15469.1","volume":"4","author":"B Oguti","year":"2019","unstructured":"Oguti B, Gibani M, Darlow C, et al. Factors influencing participation in controlled human infection models: a pooled analysis from six enteric fever studies. Wellcome Open Res. 2019;4:153. https:\/\/doi.org\/10.12688\/wellcomeopenres.15469.1.","journal-title":"Wellcome Open Res"},{"issue":"1","key":"1534_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1556264618820219","volume":"14","author":"SA Kraft","year":"2019","unstructured":"Kraft SA, Duenas DM, Kublin JG, Shipman KJ, Murphy SC, Shah SK. Exploring Ethical Concerns About Human Challenge Studies: A Qualitative Study of Controlled Human Malaria Infection Study Participants\u2019 Motivations and Attitudes. J Empir Res Hum Res Ethics. 2019;14(1):49\u201360. https:\/\/doi.org\/10.1177\/1556264618820219.","journal-title":"J Empir Res Hum Res Ethics"},{"issue":"Suppl 3","key":"1534_CR18","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1093\/cid\/ciad350","volume":"77","author":"JD Eberts","year":"2023","unstructured":"Eberts JD, Zimmer-Harwood P, Elsey JWB, Fraser-Urquhart A, Smiley T. Volunteering for Infection: Participant Perspectives on a Hepatitis C Virus Controlled Human Infection Model. Clin Infect Dis. 2023;77(Suppl 3):S224\u201330. https:\/\/doi.org\/10.1093\/cid\/ciad350.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1534_CR19","doi-asserted-by":"publisher","first-page":"e0275823","DOI":"10.1371\/journal.pone.0275823","volume":"17","author":"AA Marsh","year":"2022","unstructured":"Marsh AA, Magalhaes M, Peeler M, et al. Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials. PLoS ONE. 2022;17(11):e0275823. https:\/\/doi.org\/10.1371\/journal.pone.0275823.","journal-title":"PLoS ONE"},{"issue":"12","key":"1534_CR20","doi-asserted-by":"publisher","first-page":"e0339179","DOI":"10.1371\/journal.pone.0339179","volume":"20","author":"B Wunderlich","year":"2025","unstructured":"Wunderlich B, Chang K, Schue JL, et al. Experiences of participants in ETEC controlled human infection model studies. PLoS ONE. 2025;20(12):e0339179. https:\/\/doi.org\/10.1371\/journal.pone.0339179.","journal-title":"PLoS ONE"},{"issue":"6","key":"1534_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1559-1816.2008.00357.x","volume":"38","author":"RM Meertens","year":"2008","unstructured":"Meertens RM, Lion R. Measuring an Individual\u2019s Tendency to Take Risks: The Risk Propensity Scale. J Appl Soc Psychol. 2008;38(6):1506\u201320. https:\/\/doi.org\/10.1111\/j.1559-1816.2008.00357.x.","journal-title":"J Appl Soc Psychol"},{"issue":"5","key":"1534_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/1740774517722130","volume":"14","author":"C Grady","year":"2017","unstructured":"Grady C, Bedarida G, Sinaii N, Gregorio MA, Emanuel EJ. Motivations, enrollment decisions, and sociodemographic characteristics of healthy volunteers in phase 1 research. Clin Trials. 2017;14(5):526\u201336. https:\/\/doi.org\/10.1177\/1740774517722130.","journal-title":"Clin Trials"},{"key":"1534_CR23","unstructured":"Castor Electronic Data Capture (Castor EDC). Amsterdam, The Netherlands: Castor Research B.V.; 2016. Computer software. https:\/\/www.castoredc.com\/."},{"issue":"9","key":"1534_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/15265161.2019.1630497","volume":"19","author":"J Millum","year":"2019","unstructured":"Millum J, Garnett M. How Payment for Research Participation Can Be Coercive. Am J Bioeth. 2019;19(9):21\u201331. https:\/\/doi.org\/10.1080\/15265161.2019.1630497.","journal-title":"Am J Bioeth"},{"issue":"3","key":"1534_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.cct.2010.12.003","volume":"32","author":"L Stunkel","year":"2011","unstructured":"Stunkel L, Grady C. More than the money: A review of the literature examining healthy volunteer motivations. Contemp Clin Trials. 2011;32(3):342\u201352. https:\/\/doi.org\/10.1016\/j.cct.2010.12.003.","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"1534_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11019-022-10092-1","volume":"25","author":"J R\u00f3\u017cy\u0144ska","year":"2022","unstructured":"R\u00f3\u017cy\u0144ska J. The ethical anatomy of payment for research participants. Med Health Care Philos. 2022;25(3):449\u201364. https:\/\/doi.org\/10.1007\/s11019-022-10092-1.","journal-title":"Med Health Care Philos"},{"key":"1534_CR27","unstructured":"European Network of Research Ethics Committees. Position of the European Network of Research Ethics Committees (EUREC) on the compensation of research participants. Bonn, Germany: European Network of Research Ethics Committees; 2024. https:\/\/eurecnet.eu\/wp-content\/uploads\/Position-of-EUREC-on-compensation-of-research-participants.pdf."},{"key":"1534_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/MB.S70416","volume":"5","author":"DB Resnik","year":"2015","unstructured":"Resnik DB. Bioethical issues in providing financial incentives to research participants. MB. 2015;5:35\u201341. https:\/\/doi.org\/10.2147\/MB.S70416.","journal-title":"MB"},{"issue":"7","key":"1534_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/15265161.2025.2506328","volume":"25","author":"R Abadie","year":"2025","unstructured":"Abadie R, Anderson E, Eberts J, et al. Pursuing Fair and Just Compensation for Research Participants: An Open Letter to the Research Ethics Community. Am J Bioeth. 2025;25(7):3\u20137. https:\/\/doi.org\/10.1080\/15265161.2025.2506328.","journal-title":"Am J Bioeth"},{"issue":"3","key":"1534_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/15265161.2020.1870775","volume":"21","author":"SO McPartlin","year":"2021","unstructured":"McPartlin SO, Morrison J. What Fairness Demands: How We Can Promote Fair Compensation in Human Infection Challenge Studies and Beyond. Am J Bioeth. 2021;21(3):48\u201350. https:\/\/doi.org\/10.1080\/15265161.2020.1870775.","journal-title":"Am J Bioeth"},{"key":"1534_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1186\/s13063-022-06748-1","volume":"23","author":"D Abdulhussein","year":"2022","unstructured":"Abdulhussein D, Yap TE, Manzar H, Miodragovic S, Cordeiro F. Factors impacting participation in research during the COVID-19 pandemic: results from a survey of patients in the ophthalmology outpatient department. Trials. 2022;23:823. https:\/\/doi.org\/10.1186\/s13063-022-06748-1.","journal-title":"Trials"},{"issue":"9482","key":"1534_CR32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S0140-6736(05)66992-9","volume":"366","author":"EJ Emanuel","year":"2005","unstructured":"Emanuel EJ, Currie XE, Herman A. Undue inducement in clinical research in developing countries: is it a worry? Lancet. 2005;366(9482):336\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(05)66992-9.","journal-title":"Lancet"},{"key":"1534_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.12688\/wellcomeopenres.14439.2","volume":"3","author":"M Njue","year":"2018","unstructured":"Njue M, Njuguna P, Kapulu MC, et al. Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. Wellcome Open Res. 2018;3:39. https:\/\/doi.org\/10.12688\/wellcomeopenres.14439.2.","journal-title":"Wellcome Open Res"},{"issue":"1","key":"1534_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12910-022-00783-y","volume":"23","author":"PC Chi","year":"2022","unstructured":"Chi PC, Owino EA, Jao I, et al. Ethical considerations around volunteer payments in a malaria human infection study in Kenya: an embedded empirical ethics study. BMC Med Ethics. 2022;23(1):46. https:\/\/doi.org\/10.1186\/s12910-022-00783-y.","journal-title":"BMC Med Ethics"},{"key":"1534_CR35","doi-asserted-by":"publisher","unstructured":"Hajjar L, Al Khojah S, Jamour MA et al. Willingness to participate in medical research among adults in the United Arab Emirates (UAE): A Cross-Sectional Study. Cureus 17(4):e81894. https:\/\/doi.org\/10.7759\/cureus.81894","DOI":"10.7759\/cureus.81894"}],"container-title":["BMC Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12910-026-01534-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12910-026-01534-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12910-026-01534-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:17:28Z","timestamp":1788398248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12910-026-01534-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1186\/s12910-026-01534-z","relation":{},"ISSN":["1472-6939"],"issn-type":[{"value":"1472-6939","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Participation in this survey was entirely voluntary and without additional compensation for completing the questionnaire; participants were informed of the study purposes and data handling, followed by the statement that proceeding with the questionnaire was regarded as providing informed consent for participation. Informed consent for CHI or phase I trial participation was provided separately by all participants. The study protocol for this survey, separate from the clinical trial protocols, was reviewed by the Medical Ethical Committee Leiden, Den Haag, Delft (METC-LDD), which determined that the research did not require compliance with the Dutch Medical Research Involving Human Subjects Act (WMO).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"187"}}